BTK Inhibitor Ibrutinib for Relapsed/Refractory Waldenström’s Macroglobulinemia


BTK Inhibitor Ibrutinib for Relapsed/Refractory Waldenström’s Macroglobulinemia
Slides from a presentation at ASH 2013 and transcribed comments from a recent interview with Rafael Fonseca, MD (2/14/14)
Treon SP et al. A prospective multicenter study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom’s macroglobulinemia. Proc ASH 2013;Abstract 251.

Dr Fonseca is Getz Family Professor of Cancer and Chair of the Department of Internal Medicine at the Mayo Clinic Arizona in Scottsdale, Arizona.